1.1 Research Focus: Emerging Technologies Enabling chimeric antigen receptor (CAR) T-cell Therapies

1.2 Analysis Framework: Frost & Sullivan Core Value

1.3 Research Methodology: Five Steps Toward Success

1.4 Key Findings of Technology Breakthrough Driving Sepsis Diagnosis

2.1 Rising Pace of Cell and Gene Therapy Approvals

2.2 Regulatory and Ethical Perspectives on Gene Therapy

2.3 Rising Demand for Precision Medicine Strategies

2.4 Manufacturing Continues to be the Key Bottle Neck

2.5 II Generation Chimeric Antigen ReceptorS Likely to Dominate the Cell Therapy Landscape in the Future

2.6 CD-19 is the Most Common Target Antigen for Allogeneic CAR-T Therapies

3.1 Steady Increase in Patent Grants for CAR-T Cell Therapies

3.2 University of Pennsylvania and Novartis Lead the Patent Landscape for CAR-T Cell Therapies

3.3 China and the US Lead the Patent Landscape for CAR-T Cell Therapies

3.4 Snapshot of Key Patent Grants: Novartis

3.5 Snapshot of Key Patent Grants: Cellectis and BlueBird Bio

4.1 Key M&A Trends Across the Global Life Sciences Sector

4.2 Gene Therapy – Venture Capital Funding Assessment

4.3 Gene Therapy – Big Pharma In-licensing Deals Assessment

4.4 Strategic Insights: Cell Therapies and Gene Therapies, Viral Vector CMOs

5.1 Allogene Therapeutics

5.2 Precision BioSciences Inc.

5.3 CRISPR Therapeutics AG

5.4 Cellectis S.A.

5.5 Celyad

5.6 Bristol-Myers Squibb (BMS)

5.7 Gilead

5.8 Novartis

5.9 BlueBird Bio

5.10 Summary of the Scoring Methodology

5.11 Competitive Analysis of CAR-T Participants

6.1 Growth Opportunity: CAR-T for Solid tumors, 2020

6.2 Growth Opportunity: CAR-T for Solid tumors, 2020

Key Contacts

Key Contacts

Legal Disclaimer